Sanders Morris Harris’s Argos Therapeutics, Inc. ARGS Stock Holding History

Sanders Morris Harris’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8,061	Closed	-$24K	–	160
2017 Q4	$24K	Buy	8,061 +1,450	+22%	+$4.86K	0.01%	129
2017 Q3	$23K	Sell	6,611 -450	-6%	-$2.16K	0.01%	139
2017 Q2	$52K	Sell	7,061 -200	-3%	-$1.7K	0.02%	129
2017 Q1	$66K	Sell	7,261 -7,365	-50%	-$466K	0.02%	138
2016 Q4	$1.43M	Buy	14,626 +2,550	+21%	+$239K	0.66%	30
2016 Q3	$1.2M	Buy	12,076 +6,324	+110%	+$661K	0.36%	48
2016 Q2	$705K	Sell	5,752 -1,335	-19%	-$178K	0.16%	124
2016 Q1	$907K	Buy	+7,087	New	+$573K	0.16%	128

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Sanders Morris Harris's ARGS Position: Q1 2018 in Review

Sanders Morris Harris sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 8,061 shares — an estimated $24K sold.

Sanders Morris Harris first reported a position in ARGS in Q1 2016 and held it in 8 quarters. The position peaked at $1.43M in Q4 2016. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

Sanders Morris Harris reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Sanders Morris Harris sold 8,061 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $24K.
Sanders Morris Harris first reported a position in Argos Therapeutics, Inc. in Q1 2016 and held it in 8 quarters.
Sanders Morris Harris's Argos Therapeutics, Inc. position peaked at $1.43M in Q4 2016.
16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on Sanders Morris Harris's 13F filing for Q1 2018, filed 14 May 2018.